Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Subscribe

Sci. Signal., 2 November 2010
Vol. 3, Issue 146, p. re9
[DOI: 10.1126/scisignal.3146re9]

REVIEWS

Fibroblast Growth Factor Receptor Signaling Crosstalk in Skeletogenesis

Hichem Miraoui1,2 and Pierre J. Marie1*

1 Laboratory of Osteoblast Biology and Pathology, INSERM UMR606 and University Paris Diderot, Paris 75475, Cedex 10, France.
2 Harvard Reproductive Endocrine Sciences Center and Reproductive Endocrine Unit, Department of Internal Medicine, Massachusetts General Hospital, Boston, MA 02114, USA.

Abstract: Fibroblast growth factors (FGFs) play important roles in the control of embryonic and postnatal skeletal development by activating signaling through FGF receptors (FGFRs). Germline gain-of-function mutations in FGFR constitutively activate FGFR signaling, causing chondrocyte and osteoblast dysfunctions that result in skeletal dysplasias. Crosstalk between the FGFR pathway and other signaling cascades controls skeletal precursor cell differentiation. Genetic analyses revealed that the interplay of WNT and FGFR1 determines the fate and differentiation of mesenchymal stem cells during mouse craniofacial skeletogenesis. Additionally, interactions between FGFR signaling and other receptor tyrosine kinase networks, such as those mediated by the epidermal growth factor receptor and platelet-derived growth factor receptor {alpha}, were associated with excessive osteoblast differentiation and bone formation in the human skeletal dysplasia called craniosynostosis, which is a disorder of skull development. We review the roles of FGFR signaling and its crosstalk with other pathways in controlling skeletal cell fate and discuss how this crosstalk could be pharmacologically targeted to correct the abnormal cell phenotype in skeletal dysplasias caused by aberrant FGFR signaling.

* Corresponding author. INSERM U606, Hopital Lariboisiere, 2 rue Ambroise Pare, 75475 Paris cedex 10, France. E-mail: pierre.marie{at}inserm.fr

Citation: H. Miraoui, P. J. Marie, Fibroblast Growth Factor Receptor Signaling Crosstalk in Skeletogenesis. Sci. Signal. 3, re9 (2010).

Read the Full Text

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
FGF2 modulates cardiac remodeling in an isoform- and sex-specific manner.
E. Nusayr, D. T. Sadideen, and T. Doetschman (2013)
PHY2 1, e00088
   Abstract »    Full Text »    PDF »
The Genetics of Canine Skull Shape Variation.
J. J. Schoenebeck and E. A. Ostrander (2013)
Genetics 193, 317-325
   Abstract »    Full Text »    PDF »
Control of Mesenchymal Lineage Progression by MicroRNAs Targeting Skeletal Gene Regulators Trps1 and Runx2.
Y. Zhang, R.-l. Xie, J. Gordon, K. LeBlanc, J. L. Stein, J. B. Lian, A. J. van Wijnen, and G. S. Stein (2012)
J. Biol. Chem. 287, 21926-21935
   Abstract »    Full Text »    PDF »
The Casitas B Lineage Lymphoma (Cbl) Mutant G306E Enhances Osteogenic Differentiation in Human Mesenchymal Stromal Cells in Part by Decreased Cbl-mediated Platelet-derived Growth Factor Receptor {alpha} and Fibroblast Growth Factor Receptor 2 Ubiquitination.
N. Severe, H. Miraoui, and P. J. Marie (2011)
J. Biol. Chem. 286, 24443-24450
   Abstract »    Full Text »    PDF »
Inhibition of cellular senescence by developmentally regulated FGF receptors in mesenchymal stem cells.
D. L. Coutu, M. Francois, and J. Galipeau (2011)
Blood 117, 6801-6812
   Abstract »    Full Text »    PDF »
Conditional ablation of Pten in osteoprogenitors stimulates FGF signaling.
A. R. Guntur, M. I. Reinhold, J. Cuellar Jr, and M. C. Naski (2011)
Development 138, 1433-1444
   Abstract »    Full Text »    PDF »

To Advertise     Find Products


Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882